Cargando…

A Nomogram model for predicting the occurrence of no-reflow phenomenon after percutaneous coronary intervention using the lncRNA TUG1/miR-30e/NPPB biomarkers

BACKGROUND: Studies have shown that percutaneous coronary intervention (PCI) is considered as the essential therapeutic strategy for the patients with ST-segment elevation myocardial infarction (STEMI). However; no-reflow could still occur in a few patients after PCI. Studies have reported that biom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Chen-Kai, Cai, Ru-Ping, He, Lei, He, Shi-Rong, Liao, Jun-Yu, Su, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264104/ https://www.ncbi.nlm.nih.gov/pubmed/35813727 http://dx.doi.org/10.21037/jtd-22-481

Ejemplares similares

Emodin inhibits the progression of acute pancreatitis via regulation of lncRNA TUG1 and exosomal lncRNA TUG1
por: Wen, Xiumei, et al.
Publicado: (2021)

LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention
por: Yang, Xiheng, et al.
Publicado: (2022)

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Gupta, Sanjiv, et al.
Publicado: (2016)

The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI
por: Grancini, Luca, et al.
Publicado: (2023)

No-Reflow Phenomenon and Endothelial Glycocalyx of Microcirculation
por: Maksimenko, Alexander V., et al.
Publicado: (2012)

“No-Reflow” Phenomenon: A Contemporary Review
por: Annibali, Gianmarco, et al.
Publicado: (2022)

Correlates of the “No-Reflow” or “Slow-Flow” Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2018)

The Tug1 lncRNA locus is essential for male fertility
por: Lewandowski, Jordan P., et al.
Publicado: (2020)

Evaluation of the Clinical and Procedural Predictive Factors of no-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention
por: Abdi, Seifollah, et al.
Publicado: (2015)

hsCRP and ET-1 expressions in patients with no-reflow phenomenon after Percutaneous Coronary Intervention
por: Liu, Min, et al.
Publicado: (2017)

Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts
por: Hashemi-Jazi, Mohammad, et al.
Publicado: (2017)

LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma
por: Yun-Bo, Feng, et al.
Publicado: (2016)

Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers
por: Shemirani, Hassan, et al.
Publicado: (2014)

No-reflow phenomenon during percutaneous coronary intervention in a patient with polycythemia vera: A case report
por: Oktaviono, Yudi Her, et al.
Publicado: (2020)

LncRNA TUG1 Promotes Growth and Metastasis of Cholangiocarcinoma Cells by Inhibiting miR-29a
por: Hao, Wei Yuan, et al.
Publicado: (2020)

Knockdown of lncRNA TUG1 Enhances Radiosensitivity of Prostate Cancer via the TUG1/miR-139-5p/SMC1A Axis
por: Xiu, Dianhui, et al.
Publicado: (2020)

LncRNA TUG1 was upregulated in osteoporosis and regulates the proliferation and apoptosis of osteoclasts
por: Han, Ye, et al.
Publicado: (2019)

LncRNA TUG1 promotes the development of osteosarcoma through RUNX2
por: Sheng, Kunkun, et al.
Publicado: (2019)

LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1
por: Qiu, Nan, et al.
Publicado: (2020)

Non-pharmaco, non-invasive management of coronary no-reflow phenomenon
por: Sinha, Santosh Kumar, et al.
Publicado: (2020)

The No-reflow Phenomenon: Is it Predictable by Demographic factors and Routine Laboratory Data?
por: Namazi, Mohammadhasan, et al.
Publicado: (2021)

Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
por: Yang, Li, et al.
Publicado: (2020)

In-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention
por: Liu, Fang, et al.
Publicado: (2021)

LncRNA-TUG1 promotes the progression of infantile hemangioma by regulating miR-137/IGFBP5 axis
por: Zhou, Lili, et al.
Publicado: (2021)

CHA2DS2-VASc Score Predict No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention in Primary Percutaneous Coronary Intervention
por: Mirbolouk, Fardin, et al.
Publicado: (2018)

Nppb Neurons Are Sensors of Mast Cell-Induced Itch
por: Solinski, Hans Jürgen, et al.
Publicado: (2019)

PGC1α is required for the renoprotective effect of lncRNA Tug1 in vivo and links Tug1 with urea cycle metabolites
por: Li, Li, et al.
Publicado: (2021)

Dysregulated lncRNA TUG1 in different pulmonary artery cells under hypoxia
por: Lv, Zhenchun, et al.
Publicado: (2021)

Involvement of lncRNA TUG1 in HIV-1 Tat-Induced Astrocyte Senescence
por: Pillai, Prakash P., et al.
Publicado: (2023)

The pathogenic roles of lncRNA-Taurine upregulated 1 (TUG1) in colorectal cancer
por: Azizidoost, Shirin, et al.
Publicado: (2022)

Dexmedetomidine hydrochloride inhibits hepatocyte apoptosis and inflammation by activating the lncRNA TUG1/miR-194/SIRT1 signaling pathway
por: Gu, Xiao-Xia, et al.
Publicado: (2021)

Fluid shear stress regulates osteoblast proliferation and apoptosis via the lncRNA TUG1/miR‐34a/FGFR1 axis
por: Wang, Xingwen, et al.
Publicado: (2021)

Effects of no-reflow phenomenon on ventricular systolic synchrony in patients with acute anterior myocardial infarction after percutaneous coronary intervention
por: Wang, Le, et al.
Publicado: (2016)

The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis
por: Fajar, Jonny Karunia, et al.
Publicado: (2018)

Serum cystatin C levels relate to no-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Cheng, Chao, et al.
Publicado: (2019)

Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention
por: Badran, Hala Mahfouz, et al.
Publicado: (2020)

Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention
por: Gao, Ming-Dong, et al.
Publicado: (2020)

Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Khalfallah, Mohamed, et al.
Publicado: (2022)

The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis
por: Savic, Lidija, et al.
Publicado: (2022)

Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study
por: Jafari Afshar, Elmira, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uf46t31upb8uoebtpgm7jqp9pp